Tadalafil Tablet, Film Coated
Product Images NDC 71335-3175

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71335-3175). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 01)

Chemical structure of tadalafil, showing its molecular framework with heterocyclic rings and functional groups. The diagram illustrates the arrangement of atoms typical for tadalafil's chemical composition.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 02)

A set of four line graphs displaying the differences in blood pressure measurements (systolic and diastolic) between tadalafil and placebo over time in hours. The graphs include standing systolic BP, standing diastolic BP, supine systolic BP, and supine diastolic BP, each showing trends with error bars across a 0 to 96 hour period.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 03)

A two-panel line graph comparing the effects on systolic blood pressure of tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg over 24 hours. The top panel shows standing systolic blood pressure and the bottom panel shows supine systolic blood pressure, both plotted against time post-dose (hours). The graph includes two curves per panel for each treatment group.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 04)

A line graph showing the effect on systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo combined with 8 mg once daily doxazosin. The x-axis represents time after administration, and the y-axis shows change in systolic BP, with separate lines for 20 mg tadalafil (08:00 and 20:00) and placebo (08:00 and 20:00) groups.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 05)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) after different dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose following 5 consecutive days of administration. The y-axis represents tadalafil concentration with error bars, and the x-axis shows time up to 120 hours.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 06)

A line graph showing the change from baseline in IPSS total score over 12 weeks of treatment. Two lines compare tadalafil 5 mg and placebo groups, with the tadalafil group showing a greater decrease in score over time, indicating improved symptoms relative to placebo. Statistical significance is indicated at p<0.01.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 07)

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment between Tadalafil 5 mg and placebo groups. The vertical axis shows the change in score, with values decreasing from 0 to -6. The horizontal axis represents treatment duration in weeks (0, 1, 4, 8, 12). Two lines illustrate that Tadalafil shows a greater decrease in IPSS scores than placebo, with statistical significance indicated at week 4.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 08)

A line graph depicting least-squares mean change from baseline over 26 weeks of therapy comparing Tadalafil/Finasteride and Placebo/Finasteride groups. The x-axis shows weeks of therapy (0, 4, 12, 26), and the y-axis shows the LS mean change from baseline ranging from 0 to -7. Data points indicate greater improvement with Tadalafil/Finasteride versus placebo at each time point, with significance levels noted by letters a (p<0.001) and b (p<0.05).*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 09)

A line graph showing the change from baseline in IPSS total score over 12 weeks of treatment, comparing tadalafil 5 mg and placebo. The x-axis represents the duration of treatment in weeks (0, 2, 4, 8, 12), and the y-axis shows the change from baseline in IPSS total score, with values decreasing below zero. The tadalafil group shows a greater decrease in score over time compared to placebo, indicating improved efficacy.*

FDA Label Image

Unichem Logo (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 10)

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 11)

FDA Label Image

Label (Lbl713353175)

Label for Tadalafil Tablets, USP 10 mg oral film-coated tablets. The package contains 30 tablets labeled Rx only. The label shows the NDC number 71335-3175-1 and includes storage instructions and warnings. The product is repackaged by Bryant Ranch Prepack, Inc. and manufactured by Unichem Laboratories Ltd., with the BRP Pharmaceuticals logo visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.